Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane (R)) In Patients With Metastatic Melanoma In The Liver.

Trial Profile

Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane (R)) In Patients With Metastatic Melanoma In The Liver.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Paclitaxel (Primary) ; Paclitaxel (Primary)
  • Indications Liver metastases; Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jul 2013 Planned end date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 27 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top